Valiglurax

TargetMol
Product Code: TAR-T35028
Supplier: TargetMol
CodeSizePrice
TAR-T35028-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35028-5mg5mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35028-1mL1 mL * 10 mM (in DMSO)£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35028-10mg10mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35028-25mg25mg£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35028-50mg50mg£431.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35028-100mg100mg£606.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Valiglurax, also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson?s disease.
CAS:
1976050-09-5
Formula:
C16H10F3N5
Molecular Weight:
329.286
Pathway:
Neuroscience
Purity:
0.98
SMILES:
FC(F)(F)c1nccc2cc(Nc3n[nH]c4ncccc34)ccc12
Target:
GluR

References

Panarese JD, et al. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. ACS Med Chem Lett. 2018 Oct 16;10(3):255-260.